Theseus Pharmaceuticals (Theseus Pharmaceuticals) Inventory-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Theseus Pharmaceuticals Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Theseus Pharmaceuticals's Average Total Inventories for the quarter that ended in Sep. 2023 was $0.00 Mil. Theseus Pharmaceuticals's Revenue for the three months ended in Sep. 2023 was $0.00 Mil.

Theseus Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2023 stayed the same from Jun. 2023 (0.00) to Jun. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Theseus Pharmaceuticals Inventory-to-Revenue Historical Data

The historical data trend for Theseus Pharmaceuticals's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theseus Pharmaceuticals Inventory-to-Revenue Chart

Theseus Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Inventory-to-Revenue

Theseus Pharmaceuticals Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Inventory-to-Revenue	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Theseus Pharmaceuticals's Inventory-to-Revenue

For the Biotechnology subindustry, Theseus Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theseus Pharmaceuticals's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theseus Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Theseus Pharmaceuticals's Inventory-to-Revenue falls into.

Theseus Pharmaceuticals Inventory-to-Revenue Calculation

Theseus Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

	Inventory-to-Revenue (A: Dec. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2021 )	+	Total Inventories (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=	N/A

Theseus Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

	Inventory-to-Revenue (Q: Sep. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2023 )	+	Total Inventories (Q: Sep. 2023 ))	/	count )	/	Revenue (Q: Sep. 2023 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=

Theseus Pharmaceuticals (NAS:THRX) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Theseus Pharmaceuticals's Days Inventory for the three months ended in Sep. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2023 )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Theseus Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2023 )	/	Average Total Inventories (Q: Sep. 2023 )
	=	0	/	0
	=

Theseus Pharmaceuticals Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Theseus Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Theseus Pharmaceuticals (Theseus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theseus Pharmaceuticals Inc (NAS:THRX) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Main Street, Cambridge, MA, USA, 02142

Website

https://www.theseusrx.com

Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.

Executives

Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Foresite Capital Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Hayden Donald J Jr	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradford D. Dahms	officer: Chief Financial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Timothy P Clackson	director, officer: President and CEO	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Steven H Stein	director	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Foresite Capital Opportunity Management V, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Opportunity Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management V, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
James B. Tananbaum	10 percent owner	3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
William Shakespeare	officer: See Remarks	245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp	10 percent owner	190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Omega Fund Vi Gp Manager, Ltd.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022